FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Commission granted a marketing authorisation valid throughout the EU for Clomicalm on 1 April 1998.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za VMP Clomicalm na snazi u Europskoj uniji od 1. travnja 1998.
English: This is a summary of the European public assessment report (EPAR) for Clomicalm.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o VMP-u Clomicalm.
English: Clomicalm is a veterinary medicine used as an aid in the treatment of dogs with behavioural problems when separated from their owners, their home or other dogs.
Croatian: Clomicalm je veterinarsko-medicinski proizvod koji se primjenjuje kao pomoć u liječenju pasa koji imaju bihevioralne probleme kada su odvojeni od svojih vlasnika, svog doma ili drugih pasa.
English: What is Clomicalm and what is it used for?
Croatian: Što je Clomicalm i za što se koristi?
English: Other information about Clomicalm:
Croatian: Ostale informacije o VMP-u Clomicalm:
English: Clomicalm clomipramine hydrochloride
Croatian: Clomicalm klomipramin hidroklorid
English: Why is Clomicalm approved?
Croatian: Zašto je Clomicalm odobren?
English: Clomicalm must not be used in dogs with a known hypersensitivity to clomipramine and related medicines (known as tricyclic antidepressants).
Croatian: VMP Clomicalm ne smije se primjenjivati u pasa s prethodno utvrđenom preosjetljivosti na klomipramin i srodne lijekove (poznati kao triciklički antidepresivi).
English: If a child accidentally swallows the medicine, this could cause serious reactions.
Croatian: Ako dijete nehotice proguta VMP Clomical, to može izazvati teške reakcije.
English: It is not intended to provide practical advice on how to use Clomicalm.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni VMP-a Clomicalm.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Clomicalm's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za veterinarsko-medicinske proizvode (CVMP) pri Agenciji odlučio je da koristi od VMP-a Comicalm nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: What are the risks associated with Clomicalm?
Croatian: Koji su rizici povezani s VMP-om Clomicalm?
English: It contains the active substance clomipramine hydrochloride.
Croatian: Sadrži djelatnu tvar klomipramin hidroklorid.
English: If the product is accidentally swallowed by a person, the advice of a doctor should be sought immediately.
Croatian: Ako neka osoba nehotice proguta VMP Clomicalm, smjesta je potrebno potražiti pomoć liječnika.
English: to be effective in reducing behavioural problems in dogs associated with separation anxiety and was more effective than behavioural therapy alone on the basis of a broad spectrum of behavioural signs of anxiety including signs of high attachment to the owner.
Croatian: U terenskim ispitivanjima provedenima u SAD-u i Europi, Clomical se, u primjeni uz bihevioralnu terapiju, pokazao učinkovitim u smanjenju bihevioralnih problema u pasa koji se povezuju s anksioznosti zbog razdvajanja te učinkovitijim od same bihevioralne terapije na temelju širokog spektra bihevioralnih znakova anksioznosti, uključujući znakove velike privrženosti vlasniku.
English: How does Clomicalm work?
Croatian: Kako djeluje Clomicalm?
English: What benefits of Clomicalm have been shown in studies?
Croatian: Koje su koristi VMP-a Clomicalm utvrđene u ispitivanjima?
English: For practical information about using Clomicalm, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: Praktične informacije o primjeni VMP-a Clomicalm vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u Clomicalm, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: Such problems may include destruction of property and inappropriate defaecation and urination in the home. Clomicalm should only be given in combination with behavioural therapy.
Croatian: Takvi problemi mogu uključivati uništavanje imovine te neprimjerenu defekaciju i mokrenje u kući.
English: For more information about treatment with Clomicalm, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: Dodatne informacije o terapiji VMP-om Clomicalm vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u Clomicalm, odnosno trebaju se obratiti svojem veterinaru ili ljekarniku.
English: How is Clomicalm used?
Croatian: Kako se Clomical koristi?
English: These local reactions gradually reduce and disappear without need for treatment
Croatian: Te lokalne reakcije se postepeno smanjuju i nestaju bez potrebe za tretmanom.
English: Revaccination: 9 months after vaccination.
Croatian: Revakcinacija: 9 mjeseci nakon vakcinacije.
English: 10 DATE OF REVISION OF THE TEXT
Croatian: 10 DATUM REVIZIJE TEKSTA {MM/GGGG}
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu)
Croatian: Detaljne informacije o ovom veterinarsko-medicinskom proizvodu su dostupne na web stranici Europske agencije za lijekove http://www.ema.europa.eu/.
English: Laboratory studies in pregnant doe rabbits in the last third of gestation have not produced any evidence of a teratogenic, foetotoxic and maternotoxic effects.
Croatian: Laboratorijska istraživanja na ženkama kunića u zadnjoj trećini graviditeta nisu donijela nikakve dokaze o teratogenim niti foetotoksičnim ili maternotoksičnim učincima
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP..
Croatian: Ne koristiti ovaj veterinarsko medicinski proizvod nakon isteka roka valjanosti naznačenog na etiketi
English: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Croatian: Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e)) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja) - vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
English: Very common: nodules or swelling (< 2 cm) can be observed in the injection site, which may last 24 hours.
Croatian: Vrlo česta pojava: izrasline ili otekline (< 2 cm) mogu se pojaviti na mjestu cijepljenja i mogu trajati 24 sata.
English: EXP {month/year} Once broached use immediately.
Croatian: ROK VALJANOSTI EXP {mjesec/godina} Načeto cjepivo odmah upotrijebiti.
English: This slight temperature increase resolves spontaneously without treatment by day 5 post-vaccination.
Croatian: Blago povišenje tjelesne temperature prestaje spontano, do 5 dana nakon cijepljenja, bez liječenja.
English: EU/2/16/199/001 (5 ml) EU/2/16/199/002 (20 ml) EU/2/16/199/003 (0.5 ml)
Croatian: EU/2/16/199/002 (20 ml)
English: MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČ BIOLOŠKI DJELATNE TVAR I PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET
English: Sorbitan mono-oleate Polysorbate 80
Croatian: Mineralno ulje Tiomersal Sorbitan monooleat
English: Duration of immunity: 9 months demonstrated by challenge
Croatian: Trajanje imunosti: dokazano ispitivanjem kroz 9 mjeseci.
English: Very common: a transient temperature increase slightly above 40 ºC might occur between two or three days following vaccination.
Croatian: Vrlo često: dva ili tri dana nakon cijepljenja može se pojaviti prolazno blago povišenje temperature iznad 40ºC.
English: HIPRA BENELUX NV Tel: (+32) 9 324 21 58
Croatian: Luxembourg HIPRA BENELUX NV Tel: (+32) 9 324 21 58
English: Inactivated RHDV2, strain V-1037: ……… ≥70% cELISA40*
Croatian: Inaktivirani RHDV2, soj V-1037: ≥70% cELISA40*
English: Vial label (1, 10 or 40 doses)
Croatian: Bočice (1, 10 ili 40 doza) NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
English: {MM/YYYY}
Croatian: Lot {broj}
English: 6.5 Nature and composition of immediate packaging
Croatian: 6.5 Osobine i sastav unutarnjeg pakovanja Prozirne bočice od stakla tipa
English: Laboratorios Hipra, S.A. Avda.
Croatian: NOSITELJ ODOBRENJA ZA STAVLJANJE U PROMET LABORATORIOS HIPRA, S.A.
English: 4.9 Amounts to be administered and administration route
Croatian: 4.9 Količine koje se primjenjuju i put primjene Supkutana primjena.
English: Batch{number}
Croatian: (EXP).
English: Pregnancy
Croatian: NUSPOJAVE
English: ERAVAC Emulsion for injection for rabbits
Croatian: ERAVAC Emulzija za injekciju za kuniće
English: Laboratorios Hipra, S.A. Carretera C-63, km 48.300, Polígono Industrial El Rieral 17170 Amer
Croatian: Polígono Industrial El Rieral 17170 Amer
English: Thiomersal: ………………..0.05 mg Whitish emulsion.
Croatian: Tiomersal: ………………0,05 mg
English: 10 x 1 dose (0.5 ml).
Croatian: 10 x 1 dozom (0,5 ml) 1 x 10 doza (5 ml).
English: METHOD AND ROUTE(S) OF ADMINISTRATION
Croatian: NAČIN I PUT(EVI) PRIMJENE Supkutana primjena.
English: Thiomersal…………0.05 mg For the full list of excipients, see section 6.1.
Croatian: Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
English: Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037: ……≥70% cELISA40*
Croatian: SASTAV DJELATNIH TVARI I DRUGIH TVARI Inaktivirani virus hemoragijske bolesti kunića tipa 2 (RHDV2), soj V-1037 ≥70% cELISA40* (*) ≥70 % cijepljenih kunića u testu cELISA imaju titar protutijela 40 ili viši
English: Netherland
Croatian: KARENCIJA
English: 5 April 2016 EMA/154066/2016
Croatian: EMA/154066/2016
English: Patients with open wounds, skin problems, high fever, severe infections and severe heart and circulation problems should not have baths with valerian essential oil medicines.
Croatian: Bolesnici koji imaju otvorene rane, probleme s kožom, visoku temperaturu, teške infekcije i teške probleme sa srcem i cirkulacijom ne smiju primjenjivati kupke s lijekovima koji sadrže odoljenovo eterično ulje.
English: Valerian essential oil medicines should be used only in adults and adolescents over the age of 12 years.
Croatian: Lijekovi koji sadrže odoljenovo eterično ulje smiju se koristiti samo u odraslih osoba i adolescenata starijih od 12 godina.
English: Valerian essential oil is the common name for the essential oil extracted from the underground parts of the plant Valeriana officinalis L.
Croatian: Odoljenovo eterično ulje je uobičajeni naziv za eterično ulje koje je ekstrahirano iz podzemnih dijelova biljke Valeriana officinalis L.
English: If symptoms continue during the use of the medicine, a doctor or a healthcare practitioner should be consulted.
Croatian: Ako se simptomi nastave tijekom primjene lijeka, potrebno je obratiti se liječniku ili zdravstvenom radniku.
English: Further information on the HMPC assessment of valerian essential oil medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Croatian: Dodatne informacije o HMPC-ovoj ocjeni lijekova koji sadrže eterično ulje, uključujući pojedinosti zaključaka Povjerenstva, mogu se pronaći pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: The HMPC concluded that, on the basis of its long-standing use, valerian essential oil can be used for relief of mild symptoms of mental stress and to aid sleep.
Croatian: HMPC je zaključio da se na temelju njegove dugotrajne primjene, odoljenovo eterično ulje može koristiti za ublažavanje blagih simptoma mentalnog stresa i za poboljšanje spavanja.
English: Any applications for the licensing of medicines containing valerian essential oil have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Croatian: Svi zahtjevi za odobrenje lijekova koji sadrže odoljenovo eterično ulje moraju se podnijeti nacionalnim tijelima nadležnima za lijekove, koja ocjenjuju zahtjev za biljni lijek i uzimaju u obzir znanstvene zaključke HMPC-a.
English: The HMPC conclusions on the use of these valerian essential oil medicines for the relief of mild symptoms of mental stress and to aid sleep are based on their ‘traditional use'.
Croatian: Zaključci HMPC-a o primjeni ovih lijekova koji sadrže odoljenovo eterično ulje za ublažavanje blagih simptoma mentalnog stresa i za poboljšanje spavanja temelje se na njihovoj „tradicionalnoj primjeni”.
English: The HMPC noted the lack of clinical studies with valerian essential oil medicines, but took into account the well documented use of this herbal medicine.
Croatian: HMPC je ukazao na nedostatak kliničkih ispitivanja lijekova koji sadrže odoljenovo eterično ulj, no uzeo je u obzir dobro dokumentiranu primjenu ovog biljnog lijeka.
English: Herbal medicines containing valerian essential oil are usually available in liquid forms to be taken by mouth or used as bath additives.
Croatian: Biljni lijekovi koji sadrže odoljenovo eterično ulje najčešće su dostupni u tekućim oblicima za uporabu kroz usta ili kao dodatak kupkama.
English: Further information on the risks associated with these valerian essential oil medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Croatian: Više o rizicima povezanima s lijekovima koji sadrže odoljenovo eterično ulje, uključujući odgovarajuće mjere opreza za njihovu sigurnu primjenu, možete pronaći u monografiji pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: This summary is not intended to provide practical advice on how to use medicines containing valerian essential oil.
Croatian: Svrha ovog sažetka nije davati praktične savjete o načinu primjene lijekova koji sadrže odoljenovo eterično ulje.
English: Valerian essential oil may also be found in combination with other herbal substances in some herbal medicines.
Croatian: Odoljenovo eterično ulje može postojati također i u kombinaciji s drugim biljnim tvarima u nekim biljnim lijekovima.
English: These include nausea and abdominal cramps.
Croatian: One uključuju mučninu i grčeve u trbuhu.
English: Information on the use and licensing of valerian essential oil medicines in EU Member States should be obtained from the relevant national authorities.
Croatian: Informacije o primjeni i davanju odobrenja za lijekove koji sadrže odoljenovo eterično ulje u državama članicama EU-a mogu se dobiti od nadležnih nacionalnih tijela.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing valerian essential oil.
Croatian: Države članice EU-a uzimaju u obzir zaključke HMPC-a prilikom ocjene zahtjeva za davanje odobrenja za biljne lijekove koji sadrže odoljenovo eterično ulje.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of valerian essential oil.
Croatian: Ovaj dokument predstavlja sažetak znanstvenih zaključaka Povjerenstva za biljne lijekove (HMPC) u pogledu medicinske primjene odoljenovog eteričnog ulja.
English: Detailed instructions on how to take valerian essential oil medicines and who can use them can be found in the package leaflet that comes with the medicine.
Croatian: Detaljne upute o načinu uzimanja lijekova koji sadrže odoljenovo eterično ulje i o tome tko ih smije uzimati navedene su u uputi o lijeku koja je priložena uz lijek.
English: For more information about treatment with valerian essential oil medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Croatian: Za više informacija o liječenju lijekovima koji sadrže odoljenovo eterično ulje pročitajte uputu o lijeku priloženu uz lijek, odnosno obratite se svom liječniku ili ljekarniku.
English: Other information about valerian essential oil medicines
Croatian: Ostale informacije o lijekovima koji sadrže odoljenovo eterično ulje
English: What is valerian essential oil?
Croatian: Što je odoljenovo eterično ulje?
English: What are the risks associated with valerian essential oil medicines?
Croatian: Koji su rizici povezani s lijekovima koji sadrže odoljenovo eterično ulje?
English: For practical information about using valerian essential oil medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Croatian: Za praktične informacije o primjeni lijekova koji sadrže odoljenovo eterično ulje bolesnici trebaju pročitati uputu o lijeku priloženu uz lijek, odnosno obratiti se svom liječniku ili ljekarniku.
English: Valerian essential oil is obtained by directing steam through the underground parts of the plant.
Croatian: Odoljenovo eterično ulje dobiva se izlaganjem podzemnih dijelova biljke pari.
English: How are valerian essential oil medicines approved in the EU?
Croatian: Kako se u EU-u odobravaju lijekovi koji sadrže odoljenovo eterično ulje?
English: What evidence supports the use of valerian essential oil medicines?
Croatian: Kojim se dokazima potkrjepljuje primjena lijekova koji sadrže odoljenovo eterično ulje?
English: Side effects have been reported with valerian essential oil medicines.
Croatian: Prijavljene su nuspojave prilikom primjene lijekova koji sadrže odoljenovo eterično ulje.
English: Annex I List of medicinal products and presentations
Croatian: Dodatak I Popis naziva i farmaceutskih oblika
English: The main measure of effectiveness was overall survival (how long the patients lived).
Croatian: Glavno mjerilo djelotvornosti bila je ukupna stopa preživljenja (koliko su dugo bolesnici živjeli).
English: Onivyde (irinotecan)
Croatian: Onivyde (irinotekan)
English: Metastatic means that the cancer has spread to other parts of the body.
Croatian: Metastatski znači da se rak proširio na druge dijelove tijela.
English: This summary was last updated in 01-2019.
Croatian: Sažetak je posljednji put ažuriran u 01. 2019.
English: Onivyde (irinotecan) EMA/947/2019
Croatian: Onivyde (irinotekan) EMA/947/2019
English: Further information on the orphan designation can be found here: ema.europa.eu/medicines/human/orphan-designations/eu311933.
Croatian: Više informacija o statusu lijeka za rijetku bolest možete naći ovdje: ema.europa.eu/medicines/human/orphan-designations/eu311933.
English: What measures are being taken to ensure the safe and effective use of Onivyde?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Onivyde?
English: Further information on Onivyde can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Onivyde.
Croatian: Više informacija o lijeku Onivyde nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/Onivyde.
English: What is Onivyde and what is it used for?
Croatian: Što je Onivyde i za što se primjenjuje?
English: Onivyde received a marketing authorisation valid throughout the EU on 14 October 2016.
Croatian: Lijek Onivyde dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 14. listopada 2016.
English: Why is Onivyde authorised in the EU?
Croatian: Zašto je Onivyde odobren u EU-u?
English: The recommended dose is 70 mg per square metre of body surface given every 2 weeks together with 5-fluorouracil and leucovorin.
Croatian: Preporučena doza je 70 mg po kvadratnom metru tjelesne površine, koja se primjenjuje svaka dva tjedna zajedno s 5-fluorouracilom i leukovorinom.
English: The European Medicines Agency decided that Onivyde's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Onivyde nadmašuju s njim povezane rizike te je preporučila njegovo odobrenje za primjenu u Europskoj uniji.
English: The liposomes are expected to accumulate within the tumour and release the medicine slowly over time, thereby decreasing the rate at which irinotecan is removed from the body and allowing it to act for longer.
Croatian: Očekuje se da će se liposomi nakupljati unutar tumora i polako otpuštati lijek tijekom vremena, čime se usporava stopa uklanjanja irinotekana iz tijela te on duže djeluje.
English: Other information about Onivyde
Croatian: Ostale informacije o lijeku Onivyde
English: Side effects reported with Onivyde are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Onivyde pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: In Europe, irinotecan has been authorised for a number of years for the treatment of colorectal cancer.
Croatian: Irinotekan je u Europi odobren već niz godina za liječenje raka debelog crijeva.
English: As for all medicines, data on the use of Onivyde are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Onivyde kontinuirano se prate.
English: What are the risks associated with Onivyde?
Croatian: Koji su rizici povezani s lijekom Onivyde?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Onivyde have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Onivyde nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: The dose may be adjusted by the doctor in patients who develop severe side effects and those with particular genetic characteristics that increase the risk of side effects.
Croatian: Liječnik može prilagoditi dozu u bolesnika koji razviju ozbiljne nuspojave i u bolesnika s posebnim genetskim obilježjima koja povećavaju rizik od nuspojava.
English: An overview of Onivyde and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Onivyde i zašto je odobren u EU-u
English: By blocking the enzyme, cancer cells are prevented from multiplying and they eventually die.
Croatian: Blokiranjem enzima sprečava se umnožavanje stanica raka i one naposljetku odumiru.
English: Pancreatic cancer is rare, and Onivyde was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 December 2011.
Croatian: Rak gušterače rijetka je bolest, a Onivyde je dobio status „lijeka za rijetku bolest” 9. prosinca 2011.
English: It blocks an enzyme called topoisomerase I, which is involved in copying cell DNA, which is needed to make new cells.
Croatian: Blokira enzim naziva topoizomeraza I, koji je uključen u kopiranje staničnog DNK-a, koji je potreban za stvaranje novih stanica.
English: The study showed that the addition of Onivyde to the 5-fluorouracil plus leucovorin regimen prolonged patients' lives: patients taking the three medicines together lived for around 6.1 months, compared with 4.2 months for patients taking 5-fluorouracil plus leucovorin, and 4.9 months for patients taking Onivyde alone.
Croatian: Ispitivanjem je utvrđeno da je dodavanje lijeka Onivyde režimu 5-fluorouracil plus leukovorin produžilo život bolesnika: bolesnici koji su primali sva tri lijeka živjeli su oko 6,1 mjeseci, u usporedbi s 4,2 mjeseca u bolesnika koji su primali 5fluorouracil plus leukovorin, i 4,9 mjeseci u bolesnika koji su primali samo Onivyde.
English: For more information about using Onivyde, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Onivyde pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.